Skin Care for Cancer Patients: A Product Satisfaction Survey

Status Completed

Clinical Trial Summary

This study is being done because the investigators would like to evaluate product satisfaction of three test products (product A, product B, product C) that are available at any drug store. This will be done by measuring any changes in the subjects' answers to the Skindex-16 questionnaire at two time points (at screening and baseline visit and at follow-up visit) and by evaluating their responses to the product satisfaction survey that will be given to them by a study coordinator.

Clinical Trial Description

The primary objective of this study is to evaluate product satisfaction of the following test articles A, B, and C: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B), and Lindi Skin face wash (product C). This will be done by measuring change in Skindex-16 questionnaire at two time points (baseline and follow-up visits) and by evaluating responses to the investigator administered product satisfaction survey.

The secondary objective of this study is to see if there is any correlation between product satisfaction and grade of skin toxicity based on NCI-CTCAE v.3.0 scale.

Participants in this study will be patients seen at the Northwestern University SERIES clinic or Lurie Cancer Center who are receiving chemotherapeutic and or radiation treatments. Subjects who choose to participate complete a Skindex16 questionnaire, and will after consenting to participate, be given all three test articles A, B, and C to use daily for one month. (These test articles are currently marketed products classified by the FDA as cosmetics).

At the return visit, 1 month after baseline visit, the participant will be asked to return the test articles and complete an investigator administered product satisfaction questionnaire for each test article used. 100 participants will be surveyed. Subjects will be telephoned to check for product compliance after 1 week and 2 week intervals. ;

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

Skin Toxicity

Clinical Trial Details

NCT number	NCT00871429
Study type	Interventional
Source	Northwestern University
Contact
Status	Completed
Phase	N/A
Start date	March 2009
Completion date	August 2010

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04929834` - Novel Skin Care for Immunotherapy- Related Dermatologic Toxicities	N/A
Completed	`NCT04929847` - Novel Skin Care for Chemotherapy- Related Dermatologic Toxicities	N/A
Not yet recruiting	`NCT03606954` - Potency of Topical Corticosteroids in Combination Preparations	Phase 4
Completed	`NCT01976481` - Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27	N/A
Completed	`NCT03448731` - Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)	Phase 2
Recruiting	`NCT05109858` - Skin Toxicity by Oncological Therapies
Recruiting	`NCT04469075` - Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields	Phase 2
Recruiting	`NCT04650256` - Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences	N/A
Terminated	`NCT01317433` - Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer	N/A
Active, not recruiting	`NCT03167268` - Panitumumab Skin Toxicity Prevention Trial	Phase 2
Recruiting	`NCT06118047` - Crisaborole Ointment for Skin Toxicity Induced by Cetuximab	Phase 2